These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 8640699)

  • 1. Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: results of two randomized double blind controlled multiinstitutional trials.
    Buzdar AU; Smith R; Vogel C; Bonomi P; Keller AM; Favis G; Mulagha M; Cooper J
    Cancer; 1996 Jun; 77(12):2503-13. PubMed ID: 8640699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group.
    Buzdar AU; Jones SE; Vogel CL; Wolter J; Plourde P; Webster A
    Cancer; 1997 Feb; 79(4):730-9. PubMed ID: 9024711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group.
    Buzdar AU; Jonat W; Howell A; Jones SE; Blomqvist CP; Vogel CL; Eiermann W; Wolter JM; Steinberg M; Webster A; Lee D
    Cancer; 1998 Sep; 83(6):1142-52. PubMed ID: 9740079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma: a pooled analysis of the randomized trials.
    Carlini P; Bria E; Giannarelli D; Ferretti G; Felici A; Papaldo P; Fabi A; Nisticò C; Di Cosimo S; Ruggeri EM; Milella M; Mottolese M; Terzoli E; Cognetti F
    Cancer; 2005 Oct; 104(7):1335-42. PubMed ID: 16088965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fadrozole hydrochloride in postmenopausal patients with metastatic breast carcinoma.
    Miller AA; Lipton A; Henderson IC; Navari R; Mulagha MT; Cooper J
    Cancer; 1996 Aug; 78(4):789-93. PubMed ID: 8756373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serial serum c-erbB-2 levels in patients with breast carcinoma.
    Volas GH; Leitzel K; Teramoto Y; Grossberg H; Demers L; Lipton A
    Cancer; 1996 Jul; 78(2):267-72. PubMed ID: 8674002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Weight changes in women with metastatic breast cancer treated with megestrol acetate: a comparison of standard versus high-dose therapy.
    Cruz JM; Muss HB; Brockschmidt JK; Evans GW
    Semin Oncol; 1990 Dec; 17(6 Suppl 9):63-7. PubMed ID: 2259928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Megestrol acetate v tamoxifen in advanced breast cancer: a phase III trial of the Piedmont Oncology Association (POA).
    Muss HB; Paschold EH; Black WR; Cooper MR; Capizzi RL; Christian R; Cruz JM; Jackson DV; Stuart JJ; Richards F
    Semin Oncol; 1985 Mar; 12(1 Suppl 1):55-61. PubMed ID: 3883503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized trial of megestrol acetate with or without premarin in the treatment of potentially responsive metastatic breast cancer. A Study of the Eastern Cooperative Oncology Group (E2185).
    Cobau CD; Declercq K; Neuberg D; Ingle JN; Tormey DC
    Cancer; 1996 Feb; 77(3):483-9. PubMed ID: 8630955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response to medroxyprogesterone acetate (NSC-26386) as secondary hormone therapy for metastatic breast cancer in postmenopausal women.
    Klaassen DJ; Rapp EF; Hirte WE
    Cancer Treat Rep; 1976 Mar; 60(3):251-3. PubMed ID: 1260780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
    Berry J
    Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Megestrol acetate in the treatment of advanced post-menopausal breast cancer.
    Benghiat A; Cassidy SA; Davidson HE; Mancero FS; Pickard JG; Tyrrell CJ
    Eur J Surg Oncol; 1986 Mar; 12(1):43-5. PubMed ID: 3956753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated plasma tissue inhibitor of metalloproteinase-1 level predicts decreased response and survival in metastatic breast cancer.
    Lipton A; Ali SM; Leitzel K; Demers L; Evans DB; Hamer P; Brown-Shimer S; Pierce K; Carney W
    Cancer; 2007 May; 109(10):1933-9. PubMed ID: 17407159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fadrozole versus megestrol acetate: a double-blind randomised trial in advanced breast cancer.
    Bezwoda WR; Gudgeon A; Falkson G; Jordaan JP; Goedhals L
    Oncology; 1998; 55(5):416-20. PubMed ID: 9732218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose megestrol acetate therapy of ovarian carcinoma: a phase II study by the Northern California Oncology Group.
    Sikic BI; Scudder SA; Ballon SC; Soriero OM; Christman JE; Suey L; Ehsan MN; Brandt AE; Evans TL
    Semin Oncol; 1986 Dec; 13(4 Suppl 4):26-32. PubMed ID: 3099393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Megestrol acetate for the prevention of hot flashes.
    Loprinzi CL; Michalak JC; Quella SK; O'Fallon JR; Hatfield AK; Nelimark RA; Dose AM; Fischer T; Johnson C; Klatt NE
    N Engl J Med; 1994 Aug; 331(6):347-52. PubMed ID: 8028614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical results with megestrol acetate in patients with advanced carcinoma of the breast.
    Ansfield FJ; Kallas GJ; Singson JP
    Surg Gynecol Obstet; 1982 Dec; 155(6):888-90. PubMed ID: 7147170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer.
    Cohen MH; Johnson JR; Li N; Chen G; Pazdur R
    Clin Cancer Res; 2002 Mar; 8(3):665-9. PubMed ID: 11895893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer. Prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88.
    Thürlimann B; Beretta K; Bacchi M; Castiglione-Gertsch M; Goldhirsch A; Jungi WF; Cavalli F; Senn HJ; Fey M; Löhnert T
    Ann Oncol; 1996 Jul; 7(5):471-9. PubMed ID: 8839901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis.
    Mauri D; Pavlidis N; Polyzos NP; Ioannidis JP
    J Natl Cancer Inst; 2006 Sep; 98(18):1285-91. PubMed ID: 16985247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.